December 2, 2022

Global IV Paracetamol Market Report 2022: Rise in Postoperative Pain Cases Fueling Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “IV Paracetamol Market Size, Share, and Trend Analysis Report by Application (Surgical, Non-Surgical), By Indication (Pyrexia, Pain), by End-Use (Hospitals, Clinics), by Region (APAC, Europe), and Segment Forecasts, 2022-2030” report has been added to from ResearchAndMarkets.com offer.

The global paracetamol IV market size is expected to reach USD 994.23 million by 2030, registering a CAGR of 3.97% from 2022 to 2030, according to this report. The increasing prevalence of chronic disorders requiring pain management is expected to facilitate the growth of the industry over the forecast period. Increased use of acetaminophen to reduce reliance on opioids for pain management is expected to accelerate growth in demand for IV paracetamol. Paracetamol IV is a stable form of acetaminophen and is intended for the management of mild to moderate pain. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma because it does not interfere with platelet function.

Rising cases of patients reporting postoperative pain is expected to propel demand for drugs and products with fewer side effects. According to the article published in the International Journal of Surgery, in March 2022, 77% to 83% of patients in the United States, 80% of patients in Thailand, 76% of patients in Sweden and 29.5% of patients in Germany have reported serious cases. moderate postoperative pain. Paracetamol IV is intended for use in the treatment of acute postoperative pain and during surgical procedures, such as orthopedic, dental, and gynecological. An increase in the number of surgeries performed and patients suffering from postoperative pain is expected to create a strong demand for the products in the coming years. However, the availability of several generic products is expected to hamper the industry during the forecast period.

For example, in December 2020, Sandoz International GmbH launched generic acetaminophen injection in the United States. The product will be available at a strength of 10 mg/mL, in a 100 mL bottle for the treatment of mild to moderate conditions in combination with opioid analgesics for pediatric patients. . The major players operating in the global industry follow various strategic initiatives for the expansion of their businesses and to gain a competitive advantage over others. For example, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of Generic Acetaminophen Injection, which is an FDA-approved generic that matches Acetaminophen Injection manufactured by Mallinckrodt Pharmaceuticals.

Highlights of the IV Paracetamol Market Report

  • Based on the application, the pyrexia segment is estimated to register the fastest CAGR from 2022 to 2030

  • Segment growth attributed to rapid onset and efficacy of intravenously administered paracetamol

  • Surgical applications segment held the largest revenue share in 2021 due to increased use of IV paracetamol for postoperative pain treatment and rapid fever relief

  • North America led the global industry in 2021 due to high utilization of products to reduce the economy’s reliance on opioids for pain management

  • Companies focus on geographic expansion by adopting strategies such as collaborations, partnerships, new product launches, and strategic initiatives to maintain a competitive position in the industry.

Market dynamics

Market factors

  • Increase in cases of postoperative pain

  • Increase in the prevalence of chronic disorders

  • Increased use of intravenous paracetamol in combination with NSAIDs and narcotics

Market constraints

  • Overdose of Paracetamol IV

  • Availability of generic products

Main topics covered:

Chapter 1 Paracetamol IV Market: Methodology and Scope

Chapter 2 Paracetamol IV Market: Executive Summary

Chapter 3 Paracetamol IV Market: Industry Outlook

Chapter 4 Paracetamol IV Market: Competitive Landscape

Chapter 5 Paracetamol IV Market: Indication Business Analysis

Chapter 6 Paracetamol IV Market: Application Business Analysis

Chapter 7 Paracetamol IV Market: End-Use Business Analysis

Chapter 8 Paracetamol IV Market: Regional Business Analysis

Chapter 9 Paracetamol IV Market: Company Profiling

Companies cited

  • Mallinckrodt (Mallinckrodt Pharmaceuticals)

  • Cipla inc.

  • Lupine

  • Dr. Reddy’s Laboratories Ltd.

  • Aurobindo Pharmacy

  • Sun Pharmaceutical Industries Limited

  • Novartis AG

  • Pfizer Inc.

  • Abbott

  • Sanofi

  • Bristol-Myers Squibb Company

For more information about this report visit https://www.researchandmarkets.com/r/u600gc